Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
Go back to Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation| (NYSE: BHVN) | Delayed: 14.78 -0.72 (4.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.50 | 52 Week High | $ | |||
| Open | $15.04 | 52 Week Low | $ | |||
| Day High | $15.80 | P/E | N/A | |||
| Day Low | $14.75 | EPS | $ | |||
| Volume | 2,488,259 | |||||
